News
Yusuf Gagdi Receives Massive Support as Ward Tour Begins Ahead of APC Primaries
Member representing Pankshin/Kanke/Kanam Federal Constituency in the House of Representatives, Yusuf Adamu Gagdi, has received overwhelming support from party faithfuls and residents as he commenced a ward-to-ward tour across the constituency ahead of the All Progressives Congress (APC) primaries.
The tour, which is expected to cover wards across Pankshin, Kanke, and Kanam Local Government Areas in the coming days, began with a massive turnout of supporters in several wards in Pankshin Local Government Area.
Communities visited during the first phase of the tour included Tal, Jiblik, Garram, Chip, Langkang, Belning, Kangshu, Kadung, and Fier, where large crowds gathered to welcome the federal lawmaker.
Addressing supporters during the visits, Gagdi expressed appreciation for the warm reception and overwhelming show of support, pledging to continue delivering democratic dividends to the people.
He urged constituents to avoid politics driven by bitterness, falsehood, religion, or ethnic sentiments, stressing that leadership should be evaluated based on performance and tangible achievements.
According to him, his focus over the past eight years has been on bringing development and progress to the constituency, assuring the people that he would sustain the momentum if re-elected for another term.
The lawmaker stated that electoral choices should be based on proven records and service delivery rather than the number of times a candidate has contested or won elections.
“My appeal is for the people to vote for someone they know has worked for them and has visible evidence of performance,” he said.
Gagdi further assured constituents of his continued commitment to inclusive representation, development projects, and effective service delivery, noting that he remains dedicated to advancing the interests of the people of Pankshin, Kanke, and Kanam Federal Constituency.
He also called on APC faithfuls to support candidates with credible records during the party primaries, describing unity and support for performing leaders as critical to the progress of the party and the constituency.
Yusuf Adamu Gagdi is seeking a third term in the House of Representatives under the platform of the APC.
The National Agency for Food and Drug Administration and Control (NAFDAC) has alerted Nigerians to the circulation of a suspected counterfeit asthma medicine, warning that its use could lead to treatment failure and other serious health risks.
The agency made this known on Friday in a public alert shared on its official X account, saying the suspected falsified product, Ulmicort 0.5 mg/ml Inhalation Suspension, was detected during market surveillance conducted by pharmaceutical company AstraZeneca.
According to NAFDAC, AstraZeneca informed the agency that the product closely resembles its registered asthma medicine, Pulmicort (Budesonide) Nebulising Suspension, and could mislead healthcare professionals and patients.
Pulmicort is an inhaled corticosteroid prescribed to prevent asthma symptoms such as wheezing and shortness of breath, and is used as a maintenance treatment for people living with asthma.
Health risks
NAFDAC warned that counterfeit medicines may not meet the required standards of quality, safety and efficacy.
It explained that such products could contain incorrect ingredients, the wrong quantity of active ingredients, harmful contaminants, or no active ingredient at all.
“The use of such products can result in treatment failure, worsening of respiratory conditions, unexpected adverse effects and other serious health consequences,” the agency said.
Asthma is a chronic disease that affects the airways in the lungs, causing them to become inflamed and narrowed. It can lead to symptoms such as wheezing, coughing, chest tightness and difficulty breathing, and requires regular treatment to keep symptoms under control.
Product traced to Anambra
Providing details of the suspected counterfeit product, NAFDAC said it bears the batch number 25770416E, with a manufacturing date of June 2025 and an expiry date of May 2027.
It was reportedly found in Eastern Nigeria and traced to a distributor’s address at 15 Chizzon, Awada, Obosi North, Anambra State.
The agency added that the suspected counterfeit product is labelled as being manufactured by Legency Remedies PVT Ltd, located in Himachal Pradesh, India.
NAFDAC said it has commenced an investigation to determine the source and distribution network of the suspected counterfeit medicine.
The agency added that all its zonal directors and state coordinators have been directed to intensify surveillance and conduct mop-up operations to remove the product from circulation nationwide.
READ ALSO: NAFDAC blacklists Onifam Laboratories over regulatory violations
Advice to consumers
NAFDAC urged consumers and healthcare professionals to buy medicines only from licensed pharmacies and authorised distributors, and to examine product labels and packaging before use carefully.
The agency also encouraged the public to report suspected cases of counterfeit or substandard medicines to the nearest NAFDAC office via its toll-free line, email, or online reporting platforms.
It advised healthcare professionals and patients to promptly report any adverse reactions linked to medicinal products through its pharmacovigilance reporting channels.
Discover more from Premium Times Nigeria
Subscribe to get the latest posts sent to your email.
-
News2 days agoGovernor Mutfwang Begins Strategic Assessment to Restore Plateau’s Heritage, Boost Tourism
-
News4 days ago
Grassrunner’s Godwin Raphael Itotomi Completes Move to French Club Stade de Reims
-
News3 days ago
Elon Musk repeatedly one-upped his execs on SpaceX’s first earnings call
-
News4 days ago
AWS is helping vibe-coding startup Superblocks, and the implications are big
